<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04202796</url>
  </required_header>
  <id_info>
    <org_study_id>MR2C2001</org_study_id>
    <nct_id>NCT04202796</nct_id>
  </id_info>
  <brief_title>Catheter Ablation in Congenital Heart Disease: French National Prospective Registry</brief_title>
  <acronym>CATCH-Registry</acronym>
  <official_title>Catheter Ablation in Congenital Heart Disease: French National Prospective Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paris Cardiovascular Research Center (Inserm U970)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Chirurgical Marie Lannelongue</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique Pasteur Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Paris Cardiovascular Research Center (Inserm U970)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arrhythmias represent one of the main late complications in patients with congenital heart
      disease. Atrial arrhythmias are associated with a significant morbidity and are the first
      cause of urgent hospitalization, and sudden death from ventricular arrhythmias is a leading
      cause of death in this population.

      The exponential increase of the number of patients with congenital heart disease and the
      improvement of ablative technologies are associated with a significant increase of the number
      of catheter ablation procedures.

      Most of available studies are retrospective or include a limited number of patients.

      The aim of this study is to assess the efficacy of catheter ablation in patients with
      congenital heart disease through a national prospective registry. Secondary objectives are i)
      to identify factors associated with catheter ablation efficacy in different cardiac defects,
      ii) to describe complications associated with catheter ablation in this specific population,
      and iii) to assess the impact of catheter ablation on quality of life of patients with
      congenital heart disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Recurrence of targeted arrhythmia</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of freedom from targeted arrhythmia recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of any arrhythmia</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of freedom from any arrhythmia recurrence at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term recurrence of targeted and any arrhythmia</measure>
    <time_frame>24 months</time_frame>
    <description>Rate of freedom from targeted and any arrhythmia recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>1 month</time_frame>
    <description>Complications associated with catheter ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by SF36 score</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life change before and after catheter ablation assessed by SF36 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by EQ5D3L score</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life change before and after catheter ablation assessed by EQ5D3L score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Arrhythmia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Catheter ablation of arrhythmia</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with congenital heart disease referred for catheter ablation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with congenital heart disease referred for catheter ablation

        Exclusion Criteria:

          -  Absence of patient's consent

          -  Patient under guardianship or curatorship

          -  Pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Waldmann, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paris Cardiovascular Research Center (Inserm U970)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Victor Waldmann, MD, MPH</last_name>
    <phone>+33676098007</phone>
    <email>victor.waldmann@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georges Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Waldmann, MD, MPH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

